dendritic cell based tumor vaccination in prostate and renal cell cancer a systematic review and meta-analysis基于树突状细胞的肿瘤疫苗接种在前列腺癌和肾细胞癌的系统回顾和荟萃分析.pdfVIP

Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta- Analysis 1. ´ 1,4. 1 2 3 Andreas Draube , Nela Klein-Gonzalez , Stefanie Mattheus , Corinne Brillant , Martin Hellmich , 2 1 Andreas Engert , Michael von Bergwelt-Baildon * 1 Laboratory for Tumor and Transplantation Immunology, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany, 2 Cochrane Hematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany, 3 Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Cologne, Germany, 4 Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany Abstract Background: More than 200 clinical trials have been performed using dendritic cells (DC) as cellular adjuvants in cancer. Yet the key question whether there is a link between immune and clinical response remains unanswered. Prostate and renal cell cancer (RCC) have been extensively studied for DC-based immunotherapeutic interventions and were therefore chosen to address the above question by means of a systematic review and meta-analysis. Methodology/Principal Findings: Data was obtained after a systematic literature search from clinical trials that enrolled at least 6 patients. Individual patient data meta-analysis was performed by means of conditional logistic regression grouped by study. Twenty nine trials involving a total of 906 patients were identified in prostate cancer (17) and RCC (12). Objective response rates were 7.7% in prostate cancer and 12.7% in RCC. The combined percentag